- Home
- TXO vs CTNM Comparison
TXO vs CTNM Comparison
Compare TXO & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | TXO | CTNM |
|---|---|---|
| Founded | 2012 | 2009 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 690.8M | 575.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | TXO | CTNM |
|---|---|---|
| Price | $12.56 | $14.66 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $20.50 | $18.60 |
| AVG Volume (30 Days) | 216.0K | ★ 240.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 19.11% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $39.13 | N/A |
| Revenue Next Year | $17.86 | N/A |
| P/E Ratio | $34.94 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.12 | $3.35 |
| 52 Week High | $20.70 | $16.01 |
Technical Indicators
Market Signals| Indicator | TXO | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 64.07 | 59.13 |
| Support Level | $11.96 | $13.86 |
| Resistance Level | $12.94 | $15.39 |
| Average True Range (ATR) | 0.38 | 1.10 |
| MACD | 0.07 | -0.06 |
| Stochastic Oscillator | 73.47 | 47.35 |
Price Performance
Historical Comparison TXO
CTNM
About TXO TXO Partners L.P.
TXO Partners LP is focused on the acquisition, development, optimization, and exploitation of oil, natural gas, and natural gas liquid reserves in North America.
About CTNM Contineum Therapeutics Inc.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.